| Identification | Back Directory | [Name]
HBY 097 | [CAS]
163451-80-7 | [Synonyms]
HBY 097 Bay108979 Bay-108979 Bay 108979 Aids006671 Bay10-8979 Aids-006671 Bay 10-8979 Bay-10-8979 (S)-7-Methoxy-3,4-dihydro-2-[(methylthio)methyl]-3-thioxo-2(1H)-quinoxalinecarboxylic acid, isopropyl ester 1(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-7-methoxy-2-[(methylthio)methyl]-3-thioxo-, 1-methylethyl ester, (2S)- | [Molecular Formula]
C15H20N2O3S2 | [MDL Number]
MFCD00943200 | [MOL File]
163451-80-7.mol | [Molecular Weight]
340.46 |
| Hazard Information | Back Directory | [Uses]
Talviraline is a non-nucleoside reverse transcriptase (NNRT) inhibitor that is primarily used to inhibit the replication of human immunodeficiency virus type 1 (HIV-1). Talviraline inhibits the viral replication process by binding to a specific site of HIV-1 reverse transcriptase (RT). Talviraline can be used to study the potential countermeasures and safety of HIV-1 infection[1]. | [References]
[1] Kleim J P, et al. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication[J]. Antimicrobial agents and chemotherapy, 1995, 39(10): 2253-2257. DOI:10.1128/AAC.39.10.2253 |
|
|